Literature DB >> 27057450

The next step toward GMP-grade production of engineered immune cells.

Guido J J Kierkels1, Trudy Straetemans1, Moniek A de Witte2, Jürgen Kuball3.   

Abstract

Removing less potent T cell subsets as well as poorly- or non-engineered cells can optimize effectiveness of engineered T cell therapy against cancer. We have recently described a novel, GMP-ready method for the purification of engineered immune cells that might further boost the clinical success of cancer immunotherapy.

Entities:  

Keywords:  Adoptive immunotherapy; GMP-grade production; T cell subsets; allogeneic stem cell transplantation

Year:  2015        PMID： 27057450      PMCID： PMC4801490          DOI： 10.1080/2162402X.2015.1076608

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients.

Authors:  P Lang; T Feuchtinger; H-M Teltschik; W Schwinger; P Schlegel; M Pfeiffer; M Schumm; A-M Lang; B Lang; C P Schwarze; M Ebinger; C Urban; R Handgretinger
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

2.  Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer.

Authors:  Trudy Straetemans; Cordula Gründer; Sabine Heijhuurs; Samantha Hol; Ineke Slaper-Cortenbach; Halvard Bönig; Zsolt Sebestyen; Jürgen Kuball
Journal:  Clin Cancer Res       Date:  2015-05-19       Impact factor: 12.531

3.  γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRs.

Authors:  Cordula Gründer; Suzanne van Dorp; Samantha Hol; Esther Drent; Trudy Straetemans; Sabine Heijhuurs; Kirsten Scholten; Wouter Scheper; Zsolt Sebestyen; Anton Martens; Roland Strong; Jürgen Kuball
Journal:  Blood       Date:  2012-09-27       Impact factor: 22.113

4.  Sufficient Immunosuppression with Thymoglobulin Is Essential for a Successful Haplo-Myeloid Bridge in Haploidentical-Cord Blood Transplantation.

Authors:  Caroline A Lindemans; Liane C J Te Boome; Rick Admiraal; Els C Jol-van der Zijde; Anne M Wensing; A Birgitta Versluijs; Marc B Bierings; Jürgen Kuball; Jaap J Boelens
Journal:  Biol Blood Marrow Transplant       Date:  2015-06-26       Impact factor: 5.742

Review 5.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease.

Authors:  Benny J Chen; Xiuyu Cui; Gregory D Sempowski; Congxiao Liu; Nelson J Chao
Journal:  Blood       Date:  2003-10-09       Impact factor: 22.113

7.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.

Authors:  Carolina Berger; Michael C Jensen; Peter M Lansdorp; Mike Gough; Carole Elliott; Stanley R Riddell
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

8.  Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.

Authors:  Marie Bleakley; Shelly Heimfeld; Keith R Loeb; Lori A Jones; Colette Chaney; Stuart Seropian; Ted A Gooley; Franziska Sommermeyer; Stanley R Riddell; Warren D Shlomchik
Journal:  J Clin Invest       Date:  2015-06-08       Impact factor: 14.808

Review 9.  Hunting for clinical translation with innate-like immune cells and their receptors.

Authors:  W Scheper; C Gründer; T Straetemans; Z Sebestyen; J Kuball
Journal:  Leukemia       Date:  2013-12-18       Impact factor: 11.528

Review 10.  Orchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge.

Authors:  Moniek A de Witte; Guido J J Kierkels; Trudy Straetemans; Cedrik M Britten; Jürgen Kuball
Journal:  Cancer Immunol Immunother       Date:  2015-05-20       Impact factor: 6.968
  10 in total
  2 in total

1.  TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic mice.

Authors:  Inez Johanna; Patricia Hernández-López; Sabine Heijhuurs; Laura Bongiovanni; Alain de Bruin; Dennis Beringer; Sanne van Dooremalen; Leonard D Shultz; Fumihiko Ishikawa; Zsolt Sebestyen; Trudy Straetemans; Jürgen Kuball
Journal:  J Leukoc Biol       Date:  2020-02-05       Impact factor: 4.962

2.  Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds.

Authors:  Eline van Diest; Patricia Hernández López; Angelo D Meringa; Anna Vyborova; Froso Karaiskaki; Sabine Heijhuurs; Jan Gumathi Bormin; Sanne van Dooremalen; Mara J T Nicolasen; Lucrezia C D E Gatti; Inez Johanna; Trudy Straetemans; Zsolt Sebestyén; Dennis X Beringer; Jürgen Kuball
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 13.751
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.